Kirkland & Ellis advised Bristol-Myers Squibb Co. in its all-cash $13.4 billion sale of Celgene Corp.’s psoriasis drug Otezla to Amgen Inc., which is being advised by Sullivan & Cromwell.
The deal comes as Bristol-Myers looks to win antitrust approval to complete its planned $74 billion acquisition of Celgene, which could amount to the largest merger in the pharmaceutical industry of the past decade.
Kirkland partners Daniel Wolf, Jonathan Davis and Ryan Brissette along with David Fox led its team on the deal. The transaction also included technology and IP transactions partner Lisa Samenfeld, tax partners Sara Zablotney and Dean ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.